Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in refractory ascites: Post-marketing surveillance results

@inproceedings{Hanafusa2017SafetyAE,
  title={Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in refractory ascites: Post-marketing surveillance results},
  author={Norio Hanafusa and Ayako Isoai and Tomoaki Ishihara and Tetsuya Inoue and Ken Ishitani and Taiju Utsugisawa and Toshihiko Yamaka and Tetsuya Ito and Hiroshi Sugiyama and Atsushi Arakawa and Yosuke Yamada and Yasuo Itano and Hirokazu Onodera and Ryosuke Kobayashi and Naoko Torii and Toyoko Numata and Taihei Kashiwabara and Yoshihiro Matsuno and Michio Kato},
  booktitle={PloS one},
  year={2017}
}
We performed post-marketing surveillance to evaluate the safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART). In total, 356 CART sessions in 147 patients at 22 centers were performed. The most common primary disease was cancer (128 cases, 300 sessions). Mean amount of ascites collected was 3.7 L, and mean concentration ratio was 9.2. Mean amount of reinfused protein was 67.8 g (recovery rate, 72.0%). Performance status, dietary intake, urine volume, body weight… CONTINUE READING
1 Citations
23 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 23 references

Similar Papers

Loading similar papers…